The purpose of this research study is to learn more about the safety and effectiveness of a drug called sargramostim for improving cognitive function and memory in people with Alzheimer’s disease. Sargramostim is an investigational drug, meaning it has not been approved by the FDA to treat Alzheimer’s. This research study hopes to find out more about how sargramostim works within the body over a longer time period than previously studied.
Participants will be asked to participate in weekly visits for 24 weeks (6 months), as well as screening and follow-up visits. If determined to be eligible during screening, you will be assigned to one of two arms of the study: 1) receives study medication; 2) receives placebo (a pill or a liquid that looks like medicine but is not real)
These visits may include some of the following procedures:
Health insurance is not needed for this study.